Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Commercial Infectious Diseases

Nabriva Hopes To Relaunch Xenleta In Community Setting As Pandemic Subsides

  • Analysis

Executive Summary

Moving away from its earlier hospital-based focus with the novel antibiotic, Nabriva also thinks selling Merck & Co.’s Sivextro will provide complementary business.

You may also be interested in...



Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO

Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback. 

Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta

Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

Keeping Track: Incomplete Responses For Unusual Times; Qtrypta Is Latest CRL

Highlights from complete response letter news from the Pink Sheet’s US FDA Performance Tracker.

Table

View full table

Related Content

Scrip
Pink Sheet
Scrip
Pink Sheet

Topics

Related Companies

Tags:
Business Strategies Commercial Infectious Diseases
Latest Headlines

Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint

Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa

Pharma Giants Urge Biotechs To Get In Touch As Early As Possible

See All
UsernamePublicRestriction

Register

SC143989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By